NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
1. Basis of Presentation, Principles of Consolidation, and Use of Estimates
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared by Alliance HealthCare Services, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2015.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements of the Company include the assets, liabilities, revenues and expenses of all subsidiaries over which the Company exercises control. Intercompany transactions have been eliminated. The Company evaluates participating rights in its assessment of control in determining consolidation of joint venture partners. The Company records noncontrolling interest related to its consolidated subsidiaries that are not wholly owned. Investments in non-consolidated investees over which it exercises significant influence but does not control are accounted for under the equity method.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Critical Accounting Policies
Information with respect to the Company’s critical accounting policies which management believes could have the most significant effect on the Company’s reported results and require subjective or complex judgments by management is contained in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of the 2015 Form 10-K/A. Management believes that there have been no significant changes during the three months ended March 31, 2016 in the Company’s critical accounting policies from those disclosed in Item 7 of the 2015 Form 10-K/A.
2. Recent Accounting Pronouncements
Revenue Recognition
In May 2014, the FASB issued Accounting Standards Update (“ASU”) number 2014-09, “Revenue from Contracts with Customers (Topic 606)" — to clarify and converge the revenue recognition principles under U.S. GAAP and International Financial Reporting Standards and to develop guidance that would streamline and enhance revenue recognition requirements while also providing a more robust framework for addressing revenue issues. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance. Key provisions of the ASU involve a 5-step model specific to recognizing revenue derived from customer contracts. In addition, ASU 2014-09 provides implementation guidance on several other important topics, including the accounting for certain revenue-related costs. The Company is currently assessing the impacts this guidance may have on its consolidated financial statements and disclosures as well as the transition method it will use to adopt the guidance. The Company is considering the impacts of the new guidance on its ability to recognize revenue for certain contracts where collectability is in question. In addition, the Company will be required to capitalize costs to acquire new contracts, whereas currently, the Company expenses those costs as incurred. In August 2015, the FASB issued an amendment to provide a one year deferral of the effective date to annual reporting periods beginning on or after December 15, 2017, as well as an option to early adopt the standard for annual periods beginning on or after December 15, 2016. The Company does not plan to early adopt the standard.
Going Concern
In August 2014, the FASB issued ASU number 2014-15, "Presentation of Financial Statements—Going Concern (Subtopic 205-40)". Under U.S. GAAP, a going concern is presumed unless and until an entity’s liquidation becomes imminent. When an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, "Presentation of Financial Statements—Liquidation Basis of Accounting." However,
6
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
there may be conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern, even
if liquidation is not imminent. In those situations, financial statements should continue to be prepared under the going concern basis of accounting. ASU 2014-15 provides guidance about management’s responsibility to evaluate whether there is substantial
doubt about an entity’s ability to continue as a going concern and to determine whether to disclose information about relevant conditions and events. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for annual periods and int
erim periods thereafter. Early application is permitted. The Company is assessing the impact, if any, that the adoption of ASU 2014-15 may have on the Company's results of operations, cash flows, or financial position.
Simplifying the Presentation of Debt Issuance Costs
In April 2015, the FASB issued ASU number 2015-03, “Simplifying the Presentation of Debt Issuance Cost” that changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires entities to present such costs in the balance sheet as a direct reduction to the related debt liability rather than as a deferred cost (i.e., an asset) as required by current guidance. In August 2015, the FASB issued clarifying authoritative guidance for debt issuance costs incurred in connection with line-of-credit arrangements. The guidance states that an entity should defer and present debt issuance costs as an asset and subsequently amortize the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. ASU 2015-03 does not change the recognition or measurement of debt issuance costs and is effective for fiscal years beginning after December 15, 2015. The guidance is required to be applied retrospectively to all prior periods presented. As of December 31, 2015, the Company had $6,594 in deferred financing costs, net that was reclassified to offset long-term debt, net of current portion. The adoption of the guidance did not have a material impact on the Company's consolidated financial statements.
Balance Sheet Classification of Deferred Taxes
In November 2015, the FASB issued ASU number 2015-17, "Balance Sheet Classification of Deferred Taxes,” which will require entities to present deferred tax assets (“DTAs”) and deferred tax liabilities (“DTLs”) as noncurrent in a classified balance sheet. The ASU simplifies the current guidance, which requires entities to separately present DTAs and DTLs as current and noncurrent in a classified balance sheet. The adoption of ASU 2015-17 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Early adoption is permitted. The Company has elected to early adopt this guidance and applied it retrospectively to periods presented in the consolidated financial statements. As of December 31, 2015, the Company had $6,496 in deferred tax assets that was reclassified to long-term deferred tax liabilities. The adoption of ASU No. 2015-17 did not have a material impact on the Company’s consolidated financial statements.
Leases
In February 2016, the FASB issued ASU number 2016-02, "Leases,” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU supersedes the current guidance. The primary difference between current guidance and ASU 2015-02 is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. ASU 2016-02 also requires an entity to separate the lease components from the nonlease components (for example, maintenance services or other activities that transfer a good or service to the customer) in a contract. Only the lease components must be accounted for in accordance with this guidance. ASU 2016-02 is effective for publicly traded business entities for annual reporting periods beginning after December 15, 2018, including interim reporting periods within that reporting period. Early adoption is permitted. The Company is assessing the impact, if any, that the adoption of ASU 2016-02 may have on the Company's results of operations, cash flows, or financial position.
3. Acquisitions and Transactions
Acquisitions have been recorded using the acquisition method of accounting and, accordingly, results of their operations have been included in the Company’s consolidated financial statements since the effective date of each respective acquisition.
7
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
Thai Ho
t Transaction
On September 16, 2015, Fujian Thai Hot Investment Co., Ltd. (“Thai Hot”) agreed to purchase approximately 5,537,945 shares of Company common stock from funds managed by
Oaktree Capital Management, L.P. (“Oaktree”) and MTS Health Investors, LLC (“MTS”), and Larry C. Buckelew (together,
the “Selling Stockholders”) for approximately $102.5 million or $18.50 per share (the “Thai Hot Transaction”). In connection with the Thai Hot Transaction, Thai Hot and the Selling Stockholders agreed to bear a specified portion of the following Company expenses related to the Thai Hot Transaction: (i) 100% of the fees and expenses incurred by the Company in connection with the amendment or waiver of its credit agreement, and (ii) all reasonable and documented fees and expenses incurred by the Company in connection with the Thai Hot Transaction in excess of $1 million. In addition, subject to the approval of the Board or an authorized special committee of the Board, Thai Hot agreed to fund a new management incentive arrangement which involves the issuance of $1.5 million in cash-based awards to the Company’s management. The expenses associated with the cash-based awards will be recognized by the Company over the required service period of the awards. The Company accounted for reimbursements received prior to the Thai Hot Transaction close from the Selling Stockholders of $15,343 as capital contributions, and reimbursements received subsequent to the Thai Hot Transaction close from Thai Hot of $13,500 as capital contributions.
The Thai Hot Transaction closed on March 29, 2016. As a result of the Thai Hot Transaction, Thai Hot owns an aggregate of approximately 51.5% of the outstanding shares of common stock of the Company. The Company has not agreed to pay any management fees to Thai Hot for any financial advisory services to the Company.
2015 Acquisition
Pacific Cancer Institute, Inc.
On December 31, 2015, the Company through its Oncology Division, acquired a 95% controlling interest in the Pacific Cancer Institute (“PCI”), a state-of-the-art radiation therapy and SRS center located in Maui, Hawaii.
The purchase price consisted of $11,013 in cash, net of holdback liabilities. The Company financed this acquisition using the revolving line of credit.
As a result of this acquisition, the Company recorded goodwill of $6,505,
which largely represents intangible assets that do not qualify for separate recognition, including existing patients and the solid record of patient care in the local community.
In addition, the Company recorded intangible assets of $8,800, of which $1,800 was assigned to physician referral network, $5,400 was assigned to Certificates of Need (“CONs”), $650 was assigned to non-solicitation and non-competition agreements and $950 was assigned to trademarks, which are being amortized over 15 years. The Company recorded the intangible assets at fair value at the acquisition date, which was estimated using the income approach. A portion of the recorded goodwill and intangible assets is being amortized over 15 years for tax purposes.
The agreement includes contingent consideration arrangements, which are based on performance of the 12-month period following the transaction date. The fair value of these contingent consideration arrangements of $1,450 was estimated using monte-carlo simulations as of the acquisition date and as of March 31, 2016.
The values assigned to the various assets and liabilities acquired in this transaction are preliminary and may be subject to adjustment as the calculation of their respective fair values could be subject to change.
AHIP-Florida, LLC
On October 14, 2015, the Company, through its Interventional Healthcare Services Division, acquired a 60% controlling interest in PRC Associates, LLC, (“PRC”), a premier provider of interventional pain management healthcare with eight locations in Central Florida and the Palm Coast.
The purchase price consisted of $15,014 in cash, net of $264 cash acquired. The Company financed this acquisition using the revolving line of credit.
The purchase agreement includes a mandatory redemption provision allowing the noncontrolling interest holder to sell 10% of its noncontrolling interest to Alliance after the closing date.
8
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
As a result of this acquisition, the Company recorded goodwill of $7,606,
which largely represents intangible assets that do not qualify for separate recognitio
n, such as prominent leadership and the solid record of patient care programs that set national standards for quality coordinated care in pain management.
In addition, the Company recorded intangible assets of $15,600, of which $12,100 was assigned to phys
ician referral network, $1,800 was assigned to non-solicitation and non-competition agreements and $1,700 was assigned to trademarks, which are being amortized over 15 years. The Company recorded the intangible assets at fair value at the acquisition date,
which was estimated using the income approach. A portion of the recorded goodwill and intangible assets is being amortized over 15 years for tax purposes.
The agreement includes contingent consideration arrangements, which are based on performance of the 12-month period following the transaction date. The fair value of these contingent consideration arrangements of $2,500 was estimated using monte-carlo simulations as of the acquisition date and as of March 31, 2016.
The values assigned to the various assets and liabilities acquired in this transaction are preliminary and may be subject to adjustment as the calculation of their respective fair values could be subject to change.
Alliance-HNI, LLC and Subsidiaries
On August 1, 2015, the Company obtained an additional 15.5% interest in its previously non-consolidated investment, Alliance-HNI, LLC (“AHNI”) through a step acquisition. Prior to August 1, 2015, the Company held a noncontrolling interest in AHNI, pursuant to its ownership of Medical Consultants Imaging, Co. (“MCIC”), which held a 50% interest in a joint venture that was subsequently renamed AHNI.
Prior to the step acquisition on August 1, 2015, AHNI had three subsidiaries: Alliance-HNI Leasing Co. ("AHNIL"), Alliance-HNV PET/CT Services, LLC (“AHNVPS”), and Alliance-HNV PET/CT Leasing, LLC (“AHNVPL”). AHNI
held a 98% interest in AHNIL, which AHNI consolidated, and, effectively, a 53.4% interest in AHNVPS, which AHNI did not consolidate. In addition to the Company's original 50% investment in AHNI, it also had a 46.6% direct interest in AHNVPS prior to the step acquisition and, accordingly, the Company has historically consolidated AHNVPS and AHNVPL.
On August 1, 2015, the Company contributed its 46.6% interest in HNVPS and its rights to certain assets to AHNI in exchange for an additional 15.5% interest in AHNI. After the transaction the Company holds a 65.5% interest in AHNI which, in turn, holds all of the outstanding interest in AHNVPS. As a result of gaining a controlling interest in AHNI, the Company began consolidating AHNI effective August 1, 2015.
Pursuant to ASC 805, "Business Combinations," the transaction is considered a step acquisition and the Company was required to remeasure its previously held equity interest in AHNI at its acquisition-date fair value and recognize any resulting gain or loss. AHNVPS assets that the Company was in control of before and after the acquisition were maintained at their carrying amounts immediately before the acquisition date and no gain or loss or resulting goodwill was recognized on these assets.
The fair value of the consideration transferred was based on the net book value of the assets transferred by the Company to AHNI at the acquisition date because the Company had control of those assets before and after the transaction. The Company recorded goodwill of $2,988,
which largely represents intangible assets that do not qualify for separate recognition. In addition, the Company recorded intangible assets of $13,700. The intangible assets consist primarily of physician referral networks, trademarks, and CONs, a portion of which are being amortized over 15 years.
The values assigned to the various assets and liabilities acquired in this transaction are preliminary and may be subject to adjustment as the calculation of their respective fair values could be subject to change.
9
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The Pain Center of Arizona
On February 17, 2015, the Company purchased approximately a 59% membership interest in The Pain Center of Arizona (“TPC”), a comprehensive full-time pain management medical practice with 12 locations within the state of Arizona. The acquisition took place in two stages: a purchase of a 60% membership interest in TPC by the Company, and a 50% membership interest in Medical Practice Innovations, Inc. (“MPI”), followed by a transfer of MPI assets to TPC. The MPI transaction diluted the ownership interests of TPC, with the Company retaining approximately 59% membership interest in TPC. The purchase price consisted of $24,088 in cash, net of $234 cash acquired, and net of extinguishment of $3,071 of related-party notes receivable. The Company financed this acquisition using the revolving line of credit.
As a result of this acquisition, the Company recorded goodwill of $22,566, which largely represents intangible assets that do not qualify for separate recognition, such as prominent leadership and the solid record of patient care programs that set national standards for quality coordinated care in pain management. In addition, the Company recorded intangible assets of $24,600, of which $13,500 was assigned to physician referral network and $11,100 was assigned to trademarks, which are being amortized over 20 years. The Company recorded the intangible assets at fair value at the acquisition date, which was estimated using the income approach. A portion of the recorded goodwill and intangible assets is being amortized over 15 years for tax purposes. The fair value of noncontrolling interest related to this transaction was estimated to be $20,598 as of the acquisition date using the implied fair value based on the Company's ownership percentage. The results for the three months ended March 31, 2015 included $3,855 of net revenue and $271 of net income before income taxes, earnings from unconsolidated investees and noncontrolling interest generated by TPC.
The agreement includes contingent consideration arrangements, which are based on performance of the 12-month period following the transaction date. The fair value of these contingent consideration arrangements of $1,200 at March 31, 2016 was calculated using achieved performance estimates.
Pro Forma Impact of Acquisitions
There were no significant acquisition during the three months ended March 31, 2016. The following table provides unaudited pro forma revenues and results of operations for the three months ended March 31, 2015, as if the acquisitions had occurred on January 1, 2015. The pro forma results were prepared from financial information obtained from the sellers of the businesses, as well as information obtained during the due diligence process associated with the acquisitions. The unaudited pro forma results reflect certain adjustments related to the acquisitions, such as increased depreciation and amortization expense resulting from the stepped-up basis to fair value of assets acquired and adjustments to reflect the Company’s borrowing and tax rates. The pro forma operating results do not include any anticipated synergies related to combining the businesses. Accordingly, such pro forma operating results were prepared for comparative purposes only and do not purport to be indicative of what would have occurred had the acquisitions been made as of January 1, 2015 or of results that may occur in the future.
(In thousands, except per share amounts)
|
|
2015
|
|
Total revenues
|
|
$
|
119,687
|
|
Net income attributable to the Company
|
|
|
2,218
|
|
Basic earnings per share
|
|
|
0.21
|
|
Diluted earnings per share
|
|
|
0.20
|
|
Restructuring Plan
During the three months ended March 31, 2016, the Company recorded $231 related to restructuring charges, of which the Company recorded $31 in Selling, general and administrative expenses, and $200 in Cost of revenues, excluding depreciation and amortization. The Company also recorded $1,716 in Severance and related costs. During the three months ended March 31, 2015, the Company recorded $255 related to restructuring charges, of which the Company recorded $55 in Selling, general and administrative expenses, and $200 in Cost of revenues, excluding depreciation and amortization. The Company also recorded $259 in Severance and related costs.
10
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
4. Share-Based Payment
The Company has adopted ASC 718, “Compensation—Stock Compensation,” and has elected to follow the alternative transition method as described in ASC 718 for computing its beginning additional paid-in capital pool. In addition, the Company treats the tax deductions from stock options as being realized when they reduce taxes payable in accordance with the principles and timing under the relevant tax law.
Stock Option Plans and Awards
In November 1999, the Company adopted an employee stock option plan (as amended and restated, the “1999 Equity Plan”) pursuant to which options and awards with respect to a total of 2,205,000 shares have become available for grant. As of March 31, 2016, a total of 260,173 shares remained available for grant under the 1999 Equity Plan. Options are granted with exercise prices equal to the fair value of the Company’s common stock at the date of grant. All options have 10-year terms. Options granted after January 1, 2008 were typically time based and vest in equal tranches over three or four years. During the three months ended March 31, 2016, 71,057 options were accelerated due to a change in control in connection with the closing of the Thai Hot Transaction. During the three months ended March 31, 2015, there were no options in which vesting was accelerated.
The Company uses the Black-Scholes option pricing model to value the compensation expense associated with share-based payment awards. The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the assumptions presented in the table below. In addition, forfeitures are estimated when recognizing compensation expense and the estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.
The following weighted average assumptions were used in the estimated grant date fair value calculations for stock option awards:
|
|
Three months ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Risk free interest rate
|
|
|
1.53
|
%
|
|
|
1.65
|
%
|
Expected dividend yield
|
|
|
—
|
%
|
|
|
—
|
%
|
Expected stock price volatility
|
|
|
66.5
|
%
|
|
|
65.2
|
%
|
Average expected life (in years)
|
|
|
6.00
|
|
|
|
6.00
|
|
The Company calculates its stock price volatility and average expected life based on its own historical data. The risk free interest rates are based on the United States Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option or award.
The following table summarizes the Company’s stock option activity:
|
|
Number of
Shares
|
|
|
Weighted-
Average
Exercise Price
|
|
|
Weighted-
Average
Remaining
Contractual
Term
|
|
|
Aggregate
Intrinsic
Value
|
|
Outstanding at December 31, 2015
|
|
|
646,290
|
|
|
$
|
19.91
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
200,388
|
|
|
|
7.16
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(100,000
|
)
|
|
|
4.85
|
|
|
|
|
|
|
|
|
|
Canceled
|
|
|
(17,476
|
)
|
|
|
21.12
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2016
|
|
|
729,202
|
|
|
|
18.44
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest in the future at March 31, 2016
|
|
|
686,051
|
|
|
|
19.09
|
|
|
|
6.58
|
|
|
$
|
215
|
|
Vested and exercisable at March 31, 2016
|
|
|
478,782
|
|
|
|
22.07
|
|
|
|
5.36
|
|
|
$
|
182
|
|
11
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The following table summarizes the Company’s unvested stock option activity:
|
|
Shares
|
|
|
Weighted-
Average
Grant-Date
Fair Value
|
|
Unvested at December 31, 2015
|
|
|
158,671
|
|
|
$
|
15.01
|
|
Granted
|
|
|
200,388
|
|
|
|
4.32
|
|
Vested
|
|
|
(107,613
|
)
|
|
|
14.01
|
|
Canceled
|
|
|
(1,026
|
)
|
|
|
14.25
|
|
Unvested at March 31, 2016
|
|
|
250,420
|
|
|
$
|
6.89
|
|
Cash proceeds, along with fair value disclosures related to grants, exercises, and vesting options, are as follows (in thousands, except per share amounts):
|
|
Three months ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Proceeds from stock options exercised
|
|
$
|
485
|
|
|
$
|
6
|
|
Intrinsic value of stock options exercised (1)
|
|
|
1,365
|
|
|
|
16
|
|
Weighted-average fair value of options granted
|
|
|
7.16
|
|
|
|
14.25
|
|
Total fair value of shares vested during the period
|
|
|
1,508
|
|
|
|
372
|
|
(1)
|
The intrinsic value of stock options exercised is the amount by which the market price of the stock on the date of exercise exceeded the market price of the stock on the date of grant.
|
For the three months ended March 31, 2016 and 2015, the Company recorded share-based payment related to stock options of $1,233 and $217, respectively. At March 31, 2016, the total unrecognized fair value share-based payment related to unvested stock options granted to employees was $1,213, which is expected to be recognized over a remaining weighted-average period of 2.4 years. The valuation model applied in this calculation utilizes highly subjective assumptions that could potentially change over time, including the expected forfeiture rate and performance targets. Therefore, the amount of unrecognized share-based payment noted above does not necessarily represent the value that will ultimately be realized by the Company in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income.
Stock Awards
The 1999 Equity Plan, as amended and restated, permits the award of restricted stock, restricted stock units, stock bonus awards and performance-based stock awards (collectively referred to as “stock awards”). During the three months ended March 31, 2016, 85,206 restricted stock units were granted to employees. There were no stock awards granted to employees during the three months ended March 31, 2015. For the three months ended March 31, 2016 and 2015, the Company recorded share-based payment related to stock awards of $632 and $172, respectively.
In the third quarter of 2014, 25,000 restricted stock units (“RSU”) were granted to executive management, which vest based upon achieving certain market performance conditions. Specifically, the Company's closing stock price per common share must equal or exceed a value of $40.00 per share for 10 consecutive days between the dates of January 1, 2015 and April 21, 2017. If these conditions are not achieved before April 21, 2017, these RSUs will expire. In accordance with ASC 718, expense related to restricted stock units that vest based on achieving a market condition should not be recognized until the derived vesting period has been met, and at such time the derived vesting period becomes the requisite service period. Since the market condition has not been met, and is currently not probable of being met based on the current market condition, the Company has not recognized any expense related to these RSUs. These RSUs contain provisions that vesting may be accelerated under a change in control of the Company.
The RSU Award provided that in the event of a change in control, the unvested portion of the award will convert into the right to receive a cash amount (the “Cash Right”) equal to the number of unvested restricted stock units multiplied by the per share consideration received by the holders of the Company’s Common Stock in the change in control and the Cash Right shall vest on the six month anniversary of the consummation of the change in control subject to the executive’s continued service through such date; provided, that in the event
12
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
the executive is terminated without “cause” or for “good reason
” (each as defined in the executive’s Employment Agreement) the Cash Right shall vest in full on the date of such termination (the “Cash Right Conversion”). The Thai Hot Transaction constituted a change in control under the terms of the RSU Award agreement
and for purposes of the Cash Right Conversion, the Special Committee approved that the per share consideration received by the holders of the Company’s Common Stock upon the consummation of the Thai Hot Transaction was $18.50 per share. The monetary value
of the Cash Right of $46
3
is included as accrued compensation and related expenses on the Company’s
Condensed Consolidated Balance S
heets. For additional information on the Thai Hot Transaction, see
Note
3 –
Acquisitions and Transactions
of the Notes to
the Condensed Consolidated Financial Statements
.
The following table summarizes the Company’s restricted stock activity:
|
|
Shares
|
|
|
Weighted-
Average
Grant-Date
Fair Value
|
|
Unvested at December 31, 2015
|
|
|
74,413
|
|
|
$
|
9.18
|
|
Granted to employees
|
|
|
85,206
|
|
|
|
6.93
|
|
Vested
|
|
|
—
|
|
|
|
—
|
|
Canceled
|
|
|
—
|
|
|
|
—
|
|
Unvested at March 31, 2016
|
|
|
159,619
|
|
|
$
|
7.98
|
|
At March 31, 2016 and 2015, the total unrecognized fair value share-based payment related to stock awards granted to unaffiliated directors was $497 and $517, respectively, which is expected to be recognized over a remaining weighted-average period of 0.75 year. At March 31, 2016, unrecognized fair value share-based payments related to stock awards granted to employees was $464, which is expected to be recognized over a remaining weighted-average period of 3.0 years. At March 31, 2015, there were no unrecognized fair value share-based payments related to stock awards granted to employees.
5. Fair Value of Financial Instruments
The Company used the following methods and assumptions in estimating fair value disclosure for financial instruments:
Cash and cash equivalents
The carrying amounts of cash and cash equivalents approximate fair value due to the short-term maturity or variable rates of these instruments.
Debt
The carrying amounts of variable-rate borrowings at March 31, 2016 and December 31, 2015 approximate fair value estimates based on current market rates and credit spreads for similar debt instruments.
Contingent consideration
The carrying amounts of contingent consideration related to acquisitions at March 31, 2016 and December 31, 2015 approximate fair value using probability-adjusted, monte-carlo or achieved performance estimates.
Mandatorily redeemable noncontrolling interest
The carrying amount of mandatorily redeemable noncontrolling interest related to the PRC acquisition at March 31, 2016 and December 31, 2015 approximates fair value using the estimated implied fair value based on the Company's ownership percentage. Further discussion of the mandatorily redeemable noncontrolling interest is disclosed in
Note 3 – Acquisitions and Transactions
of the Notes to the Condensed Consolidated Financial Statements.
Derivative instruments
Fair value of derivative instruments was determined based on the income approach and standard valuation techniques to convert future amounts to a single present amount and approximates the net gains and losses that would have been realized if the contracts had been settled at each period-end.
13
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The estimated fair values of the Company’s financial instruments are as follows:
|
|
March 31, 2016
|
|
|
December 31, 2015
|
|
|
|
Carrying
Value
|
|
|
Fair
Value
|
|
|
Carrying
Value
|
|
|
Fair
Value
|
|
Cash and cash equivalents
|
|
$
|
42,691
|
|
|
$
|
42,691
|
|
|
$
|
38,070
|
|
|
$
|
38,070
|
|
Fixed-rate capital leases and debt
|
|
|
38,697
|
|
|
|
38,445
|
|
|
|
40,667
|
|
|
|
40,262
|
|
Variable-rate debt, net of deferred financing costs
|
|
|
512,519
|
|
|
|
512,858
|
|
|
|
530,424
|
|
|
|
531,926
|
|
Contingent consideration related to acquisition
|
|
|
5,150
|
|
|
|
5,150
|
|
|
|
5,750
|
|
|
|
5,750
|
|
Mandatorily redeemable noncontrolling interest
|
|
|
2,386
|
|
|
|
2,386
|
|
|
|
2,386
|
|
|
|
2,386
|
|
Derivative instruments - asset position
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Derivative instruments - liability position
|
|
|
187
|
|
|
|
187
|
|
|
|
86
|
|
|
|
86
|
|
ASC 820, “Fair Value Measurement,” applies to all assets and liabilities that are being measured and reported at fair value on a recurring basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in GAAP by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:
|
Level 1
|
Quoted market prices in active markets for identical assets or liabilities.
|
|
Level 2
|
Observable market-based inputs or unobservable inputs, including identical securities in inactive markets or similar securities in active markets that are corroborated by market data.
|
|
Level 3
|
Unobservable inputs that are not corroborated by market data.
|
The Company’s fixed and variable-rate debt represent level 2 liabilities not measured at fair value on a recurring basis. None of the Company’s instruments has transferred from one level to another.
The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of March 31, 2016:
|
|
Total
|
|
|
Quoted market
prices in active
markets (Level 1)
|
|
|
Significant other
observable
inputs
(Level 2)
|
|
|
Significant
unobservable
inputs (Level 3)
|
|
Cash and cash equivalents
|
|
$
|
42,691
|
|
|
$
|
42,691
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Contingent consideration related to acquisition
|
|
|
5,150
|
|
|
|
—
|
|
|
|
—
|
|
|
|
5,150
|
|
Mandatorily redeemable noncontrolling interest
|
|
|
2,386
|
|
|
|
—
|
|
|
|
—
|
|
|
|
2,386
|
|
Interest rate contracts - asset position
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Interest rate contracts - liability position
|
|
|
187
|
|
|
|
—
|
|
|
|
187
|
|
|
|
—
|
|
The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis by the above ASC 820 pricing levels as of December 31, 2015:
|
|
Total
|
|
|
Quoted market
prices in active
markets (Level 1)
|
|
|
Significant other
observable
inputs
(Level 2)
|
|
|
Significant
unobservable
inputs (Level 3)
|
|
Cash and cash equivalents
|
|
$
|
38,070
|
|
|
$
|
38,070
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Contingent consideration related to acquisition
|
|
|
5,750
|
|
|
|
—
|
|
|
|
—
|
|
|
|
5,750
|
|
Mandatorily redeemable noncontrolling interest
|
|
|
2,386
|
|
|
|
—
|
|
|
|
—
|
|
|
|
2,386
|
|
Interest rate contracts - asset position
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Interest rate contracts - liability position
|
|
|
86
|
|
|
|
—
|
|
|
|
86
|
|
|
|
—
|
|
14
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The Company’s derivative instruments are primarily pay-fixed, receive-variable interest rate swaps and caps based on the LIBOR swap rate. The Company has elected to use the income approach to value these derivatives, u
sing observable Level 2 market expectations at measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated, but not compelled to transact. Level 2 inputs for interest rate
swap and cap valuations are limited to quoted prices for similar assets or liabilities in active markets (specifically futures contracts on LIBOR for the first two years) and inputs other than quoted prices that are observable for the asset or liability (
specifically LIBOR cash and swap rates at commonly quoted intervals and implied volatilities for options). ASC 820 states that the fair value measurement of an asset or liability must reflect the nonperformance risk of the entity and the counterparty. Ther
efore, the impact of the counterparty’s creditworthiness and the Company’s creditworthiness has also been factored into the fair value measurement of the derivative instruments. For additional information please see
Note 9 - Derivatives
of the Notes to the
Condensed
Consolidated Financial Statements.
6. Goodwill and Intangible Assets
Changes in the carrying amount of goodwill are as follows:
Balance at December 31, 2014
|
|
$
|
63,864
|
|
Goodwill acquired during the period
|
|
|
38,918
|
|
Impairment charges
|
|
|
—
|
|
Adjustments to goodwill during the period
|
|
|
—
|
|
Balance at December 31, 2015
|
|
|
102,782
|
|
Goodwill acquired during the period
|
|
|
929
|
|
Impairment charges
|
|
|
—
|
|
Adjustments to goodwill during the period
|
|
|
415
|
|
Balance at March 31, 2016
|
|
$
|
104,126
|
|
Gross goodwill
|
|
$
|
278,370
|
|
Accumulated impairment charges
|
|
|
(174,244
|
)
|
Balance at March 31, 2016
|
|
$
|
104,126
|
|
Intangible assets consisted of the following:
|
|
March 31, 2016
|
|
|
December 31, 2015
|
|
|
|
Gross Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Intangible
Assets, net
|
|
|
Gross Carrying
Amount
|
|
|
Accumulated
Amortization
|
|
|
Intangible
Assets, net
|
|
Amortizing intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer contracts
|
|
$
|
188,116
|
|
|
$
|
(94,324
|
)
|
|
$
|
93,792
|
|
|
$
|
186,316
|
|
|
$
|
(92,280
|
)
|
|
$
|
94,036
|
|
Other
|
|
|
38,685
|
|
|
|
(20,940
|
)
|
|
|
17,745
|
|
|
|
38,522
|
|
|
|
(20,540
|
)
|
|
|
17,982
|
|
Total amortizing intangible assets
|
|
$
|
226,801
|
|
|
$
|
(115,264
|
)
|
|
$
|
111,537
|
|
|
$
|
224,838
|
|
|
$
|
(112,820
|
)
|
|
$
|
112,018
|
|
Intangible assets not subject to amortization
|
|
|
|
|
|
|
|
|
|
|
50,905
|
|
|
|
|
|
|
|
|
|
|
|
50,905
|
|
Total other intangible assets
|
|
|
|
|
|
|
|
|
|
$
|
162,442
|
|
|
|
|
|
|
|
|
|
|
$
|
162,923
|
|
15
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
In 2016, t
he Company intends to perform its
annual impairment test in the fourth quarter for goodwill and indefinite life intangible assets, absent of other events occurring or changes in circumstances that would more likely than not reduce the fair value of a reporting unit below its carrying amou
nt. The Company compares the fair value of its reporting units to its carrying amount to determine if there is potential impairment. The fair value of the reporting unit is determined by an income approach and a market capitalization approach. Significant
management judgment is required in the forecasts of future operating results that are used in the income approach. The estimates that the Company has used are consistent with the plans and estimates that it uses to manage its business. The Company bases it
s fair value estimates on forecasted revenue and operating costs which include a number of factors including, but not limited to, securing new customers, retention of existing customers, growth in
radiology, oncology and interventional
revenues and the imp
act of continued cost savings initiatives. However, it is possible that plans and estimates may change. Based on financial information as of March 31, 2016, impairment testing was not required during the three months then ended. Although the Company conclu
ded that no impairment was present in its intangible assets in the three months of 2016, the Company intends to test its Goodwill and other intangibles assets for impairment during the fourth quarter of 2016, as described above.
The Company uses the estimated useful life to amortize customer contracts, which is a weighted-average of 15 years. Other intangible assets subject to amortization are estimated to have a weighted-average useful life of six years. Amortization expense for intangible assets subject to amortization was $2,443 and $2,035 for the quarters ended March 31, 2016 and 2015, respectively. The intangible assets not subject to amortization represent certificates of need and regulatory authority rights which have indefinite useful lives.
As of March 31, 2016, estimated annual amortization expense for each of the fiscal years ending December 31, is presented below:
Remainder of 2016
|
|
$
|
7,189
|
|
2017
|
|
|
9,192
|
|
2018
|
|
|
8,831
|
|
2019
|
|
|
8,347
|
|
2020
|
|
|
7,832
|
|
Thereafter
|
|
|
70,146
|
|
7. Supplemental Balance Sheet Information
Other accrued liabilities as of March 31, 2016 and December 31, 2015 are as follows:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Systems rental and maintenance costs
|
|
$
|
4,255
|
|
|
$
|
1,808
|
|
Site rental fees
|
|
|
1,407
|
|
|
|
1,121
|
|
Property and sales taxes payable
|
|
|
8,594
|
|
|
|
8,695
|
|
Self-insurance accrual
|
|
|
2,294
|
|
|
|
2,037
|
|
Legal fees
|
|
|
1,498
|
|
|
|
1,971
|
|
Deferred gain on sale of equipment
|
|
|
87
|
|
|
|
312
|
|
Equipment purchases
|
|
|
3,295
|
|
|
|
4,756
|
|
Contingent consideration related to acquisition
|
|
|
5,150
|
|
|
|
5,750
|
|
Mandatorily redeemable noncontrolling interest
|
|
|
2,386
|
|
|
|
2,386
|
|
Other accrued liabilities
|
|
|
11,121
|
|
|
|
7,617
|
|
Total
|
|
$
|
40,087
|
|
|
$
|
36,453
|
|
16
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
Plant, property
and equipment, net of depreciation, as of March 31, 2016 and December 31, 2015 are as follows:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Furniture and fixtures
|
|
$
|
4,921
|
|
|
$
|
4,825
|
|
Office equipment
|
|
|
73,685
|
|
|
|
71,245
|
|
Transportation and service equipment
|
|
|
10,360
|
|
|
|
5,884
|
|
Major equipment
|
|
|
767,528
|
|
|
|
758,718
|
|
Tenant improvements
|
|
|
42,635
|
|
|
|
42,792
|
|
Buildings and land
|
|
|
340
|
|
|
|
340
|
|
|
|
|
899,469
|
|
|
|
883,804
|
|
Accumulated depreciation
|
|
|
(711,772
|
)
|
|
|
(706,616
|
)
|
Plant, property and equipment, net
|
|
$
|
187,697
|
|
|
$
|
177,188
|
|
8. Long-Term Debt and Senior Subordinated Credit Facility
Long-term debt consisted of the following:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Term loan facility
|
|
$
|
501,574
|
|
|
$
|
502,874
|
|
Discount on term loan facility
|
|
|
(1,696
|
)
|
|
|
(1,823
|
)
|
Revolving credit facility
|
|
|
28,500
|
|
|
|
19,500
|
|
Equipment under capital leases
|
|
|
12,083
|
|
|
|
13,006
|
|
Equipment debt
|
|
|
41,974
|
|
|
|
44,128
|
|
Deferred financing costs, net
|
|
|
(31,219
|
)
|
|
|
(6,594
|
)
|
Long-term debt, including current portion
|
|
|
551,216
|
|
|
|
571,091
|
|
Less current portion
|
|
|
19,916
|
|
|
|
20,406
|
|
Long-term debt
|
|
$
|
531,300
|
|
|
$
|
550,685
|
|
Equipment debt, collateralized by equipment, have interest rates ranging from 1.93% to 7.50% and are payable in various monthly principal and interest payments through 2021. Equipment under capital leases, collateralized by equipment, have interest rates ranging from 4.00% to 8.61% and are payable in various monthly principal and interest payments through 2021.
Credit Facility and Senior Secured Term Loan Refinancing
On June 3, 2013, the Company replaced its existing credit facility with a new senior secured credit agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Credit Agreement”). The Credit Agreement consists of (i) a $340,000, six-year term loan facility, (ii) a $50,000, five-year revolving loan facility, including a $20,000 sublimit for letters of credit, (iii) uncommitted incremental loan facilities of $100,000 of revolving or term loans, plus an additional amount if the Company’s pro forma leverage ratio is less than or equal to 3.25, subject to receipt of lender commitments and satisfaction of specified conditions, and (iv) an $80,000 delayed draw term loan facility, which was required to be drawn within thirty days of June 3, 2013 and used for the redemption of the Company's $190,000 of 8% Senior Notes (“Notes”).
On July 3, 2013 the delayed draw term loan facility was utilized, of which the proceeds were used to redeem $80,000 in aggregate principal amount of the Company's outstanding Notes that were originally issued in December 2009 as a cash tender offer for any and all of its outstanding 7.25% Notes originally issued in December of 2004. The delayed draw term loan facility converted into, and matched the terms of, the new $340,000 term loan facility.
17
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
Borrowings under the Credit Agreement bear interest through maturity at
a variable rate based upon, at the Company's option, either the LIBOR or the base rate (which is the highest of the administrative agent’s prime rate, one-half of 1.00% in excess of the overnight federal funds rate, and 1.00% in excess of the one-month LI
BOR rate), plus, in each case, an applicable margin. With respect to the term loan facilities, the applicable margin for LIBOR loans is 3.25% per annum, and with respect to the revolving loan facilities, the applicable margin for LIBOR loans ranges, based
on the applicable leverage ratio, from 3.00% to 3.25% per annum, in each case, with a LIBOR floor of 1.00%. The applicable margin for base rate loans under the term loan facilities is 2.25% per annum and under the revolving loan facility ranges, based on t
he applicable leverage ratio, from 2.00% to 2.25% per annum. Prior to the refinancing of the term loan facilities, the applicable margin for base rate loans was 4.25% per annum and the applicable margin for revolving loans was 5.25% per annum, with a LIBOR
floor of 2.00%. The Company is required to pay a commitment fee which ranges, based on the applicable leverage ratio, from 0.38% to 0.50% per annum on the undrawn portion available under the revolving loan facility and variable per annum fees with respect
to outstanding letters of credit.
During the first five and one-half years after the closing date, and including the full amount of the delayed draw term loan facility, the Company is required to make quarterly amortization payments of the term loans in the amount of $1,050. The Company is also required to make mandatory prepayments of term loans under the Credit Agreement, subject to specified exceptions, from excess cash flow (as defined in the Credit Agreement) and with the proceeds of asset sales, debt issuances and specified other events.
Obligations under the Credit Agreement are guaranteed by substantially all the Company's direct and indirect domestic subsidiaries. The obligations under the Credit Agreement and the guarantees are secured by a lien on substantially all tangible and intangible property, and by a pledge of all of the shares of stock and limited liability company interests of the Company's direct and indirect domestic subsidiaries, of which the Company now owns or later acquires more than a 50% interest, subject to limited exceptions.
In addition to other covenants, the Credit Agreement places limits on the ability of the Company and its subsidiaries to declare dividends or redeem or repurchase capital stock, prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions and asset sales, transact with affiliates and alter the business conducted by the Company and its subsidiaries.
The Credit Agreement also contains a leverage ratio covenant requiring the Company to maintain a maximum ratio of consolidated total debt to consolidated adjusted EBITDA expense that ranges from 4.95 to 1.00 to 4.30 to 1.00. At March 31, 2016, the Credit Agreement requires a maximum leverage ratio of not more than 4.55 to 1.00. The Credit Agreement eliminated the interest coverage ratio covenant that the Company was subject to maintain prior to the refinancing. Failure to comply with the covenants in the Credit Agreement could permit the lenders under the Credit Agreement to declare all amounts borrowed under the Credit Agreement, together with accrued interest and fees, to be immediately due and payable, and to terminate all commitments under the Credit Agreement.
Incremental Term Loan
On October 11, 2013, the Company entered into an amendment to the Credit Agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “First Amendment”). Pursuant to the First Amendment, the Company raised
$70,000
in incremental term loan commitments to repurchase the remaining Notes. On December 2, 2013, the Company borrowed $70,000 of incremental term loans and, with such proceeds plus borrowings under its revolving line of credit and cash on hand, completed the redemption of all its outstanding Notes on December 4, 2013.
On June 19, 2015, the Company entered into a second amendment to the Credit Agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Second Amendment”). Pursuant to the Second Amendment, the Company raised the remaining $30,000 in incremental term loan commitments. The funds were used to repay all outstanding borrowings under the Company's revolving credit facility, pay fees and expenses related to the Second Amendment, and general corporate purposes. The Second Amendment did not impact the borrowing capacity on the revolving credit facility, which remains at $50,000.
18
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The incremental term loan under the Second Amendment was funded at 99.0% of principal amount and will mature on the same date as the existing term loan under the Company’s credit agreement
,
on June 3, 2019.
Upon funding, the incremental term loans were converted to match all the terms of existing term loans. Interest on the incremental term loan is calculated, at the Company’s option, at a base rate plus a 2.25% margin or LIBOR plus a 3.25% margin, subject to
a 1.00% LIBOR floor.
The quarterly amortization payments of all term loans under the credit facility for the first five and one-half years was initially established at $1,050. The quarterly amortization payment was increased to $1,300 in June 2015, pursuant to the Second Amendment.
On March 29, 2016, the Company entered into a third amendment to the Credit Agreement with Credit Suisse AG, Cayman Islands Branch, as administrative agent, and the other lenders party thereto (the “Third Amendment”). Pursuant to the Third Amendment, (i) the defined term “Investors” was amended to include THAIHOT Investment Company Limited, so that the sale by the Selling Stockholders would not be deemed to constitute a change of control and (ii) the soft call provision was reinstated to commence on the date the Third Amendment is effective and end the date that is twelve months after such commencement.
Under the soft call provision, if the Company makes a voluntary prepayment of any Term Loan or prepays, refinances, substitutes or replaces any Term Loan, then the Company shall pay to the administrative agent, for the ratable account of each of the lenders holding Term Loans a prepayment premium equal to 1.0% of the aggregate principal amount of the Term Loans so prepaid, refinanced, substituted or replaced.
In connection with the Third Amendment, the Company paid fees totaling $25.0 million, which were capitalized and amortized on a straight-line basis as interest expense over the term of the Credit Agreement.
As of March 31, 2016, the Company’s ratio of consolidated total debt to Consolidated Adjusted EBITDA calculated pursuant to the Credit Agreement was 4.22 to 1.00. As of March 31, 2016, the Company had $16.7 million of available borrowings under the revolving line of credit, net of $28.5 million outstanding on the revolving line of credit and $4.8 million outstanding in letters of credit.
Notes Payable and Line of Credit with PNC
As a result of the step acquisition on August 1, 2015, and subsequent consolidation of AHNI, the Company had notes payable to PNC totaling $6,139 at March 31, 2016. The notes payable are due in various installments through December 2020 at interest rates between 1.83% and 1.94% per annum. The notes are also collateralized by equipment and contain restrictive covenants. AHNI also has a $2,000 line of credit with PNC, with interest calculated based on LIBOR plus 1.5%. As of March 31, 2016, there was $191 amount outstanding on the line of credit. For additional information on the step acquisition, refer to
Note 3 – Acquisitions and Transactions
of the Notes to the Condensed Consolidated Financial Statements
.
9. Derivatives
The Company accounts for derivative instruments and hedging activities in accordance with the provisions of ASC 815, “Derivatives and Hedging.” Management generally designates derivatives in a hedge relationship with the identified exposure on the date the Company enters into a derivative contract, as disclosed below. The Company has only executed derivative instruments that are economic hedges of exposures that can qualify in hedge relationships under ASC 815. The Company formally documents all relationships between hedging instruments and hedged items, as well as the risk-management objective and strategy for undertaking various hedge transactions. In this documentation, the Company specifically identifies the firm commitment or forecasted transaction that has been designated as a hedged item and states how the hedging instrument is expected to hedge the risks related to the hedged item. The Company formally assesses effectiveness of its hedging relationships, both at the hedge inception and on an ongoing basis, then measures and records ineffectiveness. The Company would discontinue hedge accounting prospectively (i) if it is determined that the derivative is no longer effective in offsetting change in the cash flows of a hedged item, (ii) when the derivative expires or is sold, terminated or exercised, (iii) because it is probable that the forecasted transaction will not occur, or (iv) if management determines that designation of the derivative as a hedge instrument is no longer appropriate. The Company’s derivatives are recorded on the balance sheet at their fair value. For additional information refer to
Note 5 – Fair Value of Financial Instruments
of the Notes to the Condensed Consolidated Financial Statements. For derivatives accounted for as cash flow hedges, any effective unrealized gains or
19
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
losses on fair value are included in comprehensive income (loss),
net of tax, and any ineffective gains or losses are recognized in income immediately. Amounts recorded in comprehensive income (loss) are reclassified to earnings when the hedged item impacts earnings.
Cash Flow Hedges
Interest Rate Cash Flow Hedges
The Company has entered into multiple interest rate swap and cap agreements to hedge the future cash interest payments on portions of its variable rate bank debt. For the three months ended March 31, 2016 and 2015, the Company had interest rate swap and cap agreements to hedge approximately $264,738 and $257,902 of its variable rate bank debt, respectively, or 45.5% and 48.3% of total debt, respectively. Over the next twelve months, the Company expects to reclassify $727 from accumulated other comprehensive income (loss) to interest expense and other, net.
In the fourth quarter of 2012, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in December 2017, had a notional amount of $1,928 as of March 31, 2016. Under the terms of this agreement, the Company receives one-month LIBOR plus 2.50% and pays a fixed rate of 3.75%. The net effect of the hedge is to convert interest expense to a fixed rate of 3.75%, as the underlying debt incurred interest based on one-month LIBOR plus 2.50%.
In the first quarter of 2013, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in April 2018, had a notional amount of $1,831 as of March 31, 2016. Under the terms of this agreement, the Company receives one-month LIBOR plus 2.00% and pays a fixed rate of 2.87%. The net effect of the hedge is to convert interest expense to a fixed rate of 2.87%, as the underlying debt incurred interest based on one-month LIBOR plus 2.00%.
In the fourth quarter of 2013, the Company entered into five interest rate cap agreements ("2013 Caps"). The 2013 Caps, which mature in December 2016, had a notional amount of $250,000 and were designated as cash flow hedges of future cash interest payments associated with a portion of the Company’s variable rate bank debt. Under these arrangements, the Company has purchased a cap on LIBOR at 2.50%. The Company paid $815 to enter into the caps, which is being amortized through interest expense and other, net over the life of the agreements.
In the fourth quarter of 2014, the Company entered into an interest rate swap agreement in connection with equipment financing. The swap, which matures in November 2019, had a notional amount of $1,261 as of March 31, 2016. Under the terms of this agreement, the Company receives one-month LIBOR and pays a fixed rate of 1.34%. The net effect of the hedge is to convert interest expense to a fixed rate of 1.34%, as the underlying debt incurred interest based on one-month LIBOR.
In the third quarter of 2015, the Company acquired eight non-designated interest rate swaps (the "AHNI Swaps") as a result of the step acquisition of AHNI. The AHNI swaps mature on various dates ranging from April 2017 through April 2020 and had notional amounts totaling $2,967 as of March 31, 2016. Under the terms of these arrangements, the Company receives one-month LIBOR and pays fixed rates ranging from 0.85% to 1.17%. The changes in fair market value of the AHNI Swaps are recorded in interest expense and other, net, as incurred.
In the fourth quarter of 2015, the Company entered into two interest rate swap agreements in connection with equipment financing. The swaps mature from December 2020 through December 2021 and had notional amounts totaling $6,751 as of March 31, 2016. Under the terms of these agreements, the Company receives one-month LIBOR and one-month LIBOR plus 2.00% and pays fixed rates of 1.37% and 3.69%, respectively. The net effect of these hedges is to convert interest expense to fixed rates of 1.37% and 3.69%, as the underlying debt incurred interest based on one-month LIBOR and one-month LIBOR plus 2.00%, respectively.
20
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The Effect of Designated Derivative Instruments on the
Condensed Consolidated
Statement of Oper
ations
and Comprehensive (Loss) Income
For the Three Months Ended March 31, 2016
Derivatives in
Cash
Flow Hedging
Relationships
|
|
Amount of Gain (Loss)
Recognized in OCI on
Derivatives (Effective
Portion)
|
|
|
Location of
Gain (Loss)
Reclassified from
Accumulated OCI
into Income
(Effective Portion)
|
|
Amount of Gain (Loss)
Reclassified from
Accumulated OCI into
Income (Effective
Portion)
|
|
|
Location of Gain
(Loss) Recognized in
Income on Derivatives
(Ineffective Portion)
|
|
Amount of Gain (Loss)
Recognized in Income
on Derivatives
(Ineffective Portion)
|
|
Interest rate
contracts
|
|
$
|
(79
|
)
|
|
Interest expense
and other, net
|
|
$
|
(83
|
)
|
|
Interest expense
and other, net
|
|
$
|
—
|
|
Total
|
|
$
|
(79
|
)
|
|
|
|
$
|
(83
|
)
|
|
|
|
$
|
—
|
|
The Effect of Designated Derivative Instruments on the Condensed Consolidated Statement of Operations and Comprehensive (Loss) Income
For the Three Months Ended March 31, 2015
Derivatives in
Cash
Flow Hedging
Relationships
|
|
Amount of Gain (Loss)
Recognized in OCI on
Derivatives (Effective
Portion)
|
|
|
Location of
Gain (Loss)
Reclassified from
Accumulated OCI
into Income
(Effective Portion)
|
|
Amount of Gain (Loss)
Reclassified from
Accumulated OCI into
Income (Effective
Portion)
|
|
|
Location of Gain
(Loss) Recognized in
Income on Derivatives
(Ineffective Portion)
|
|
Amount of Gain (Loss)
Recognized in Income
on Derivatives
(Ineffective Portion)
|
|
Interest rate
contracts
|
|
$
|
189
|
|
|
Interest expense
and other, net
|
|
$
|
11
|
|
|
Interest expense
and other, net
|
|
$
|
1
|
|
Total
|
|
$
|
189
|
|
|
|
|
$
|
11
|
|
|
|
|
$
|
1
|
|
The effect of non-designated derivative instruments on the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the three months ended March 31, 2016 and 2015 was immaterial.
10. Income Taxes
For the three months ended March 31, 2016, the Company recorded income tax benefit of $945, or 44.3%, of the Company’s pretax income. For the three months ended March 31, 2015, the Company recorded income tax expense of $1,572, or 47.3%, of the Company’s pretax income. The Company’s effective tax rate for the three months ended March 31, 2016 and 2015 differed from the federal statutory rate principally as a result of state income taxes and permanent non-deductible tax items, including share-based payments, unrecognized tax benefits and other permanent differences.
As of March 31, 2016, the Company has provided a liability for $242 of unrecognized tax benefits related to various federal and state income tax matters. The tax-effected amount that would reduce the Company’s effective income tax rate if recognized is $203. As of March 31, 2015, the Company has provided a liability for $285 of unrecognized tax benefits related to various federal and state income tax matters. The tax-effected amount that would reduce the Company’s effective income tax rate if recognized is $243.
The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. As of March 31, 2016 and 2015, the Company had approximately $11 and $14, respectively, in accrued interest and penalties related to unrecognized tax benefits.
21
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The Company is subject to United States federal income tax as well as income tax of multiple state tax jurisdictions. Th
e Company is currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended December 31, 2012 through 2015. The Company’s and its subsidiaries’ state income tax returns are open to audit under the applicable st
atutes of limitations for the years ended December 31, 2011 through 2015. The Company does not anticipate a significant change to the total amount of unrecognized tax benefits within the next 12 months.
11. Earnings Per Common Share
Basic net (loss) income per share is computed utilizing the two-class method and is calculated based on the weighted-average number of common shares outstanding during the periods presented, excluding unvested restricted stock units which do not contain nonforfeitable rights to dividend and dividend equivalents.
Diluted net (loss) income per share is computed using the weighted-average number of common and common equivalent shares outstanding during the periods utilizing the two-class method for stock options, unvested restricted stock and unvested restricted stock units. Potentially dilutive securities are not considered in the calculation of net loss per share as their impact would be anti-dilutive.
The following table sets forth the computation of basic and diluted net (loss) income per share (amounts in thousands, except per share amounts):
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Numerator:
|
|
|
|
|
|
|
|
|
Net (loss) income attributable to Alliance HealthCare
Services, Inc.
|
|
$
|
(1,190
|
)
|
|
$
|
1,751
|
|
Denominator:
|
|
|
|
|
|
|
|
|
Weighted-average shares-basic
|
|
|
10,779
|
|
|
|
10,714
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
Employee stock options
|
|
|
—
|
|
|
|
128
|
|
Weighted-average shares-diluted
|
|
|
10,779
|
|
|
|
10,842
|
|
Net (loss) income per common share attributable to Alliance
HealthCare Services, Inc.:
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.11
|
)
|
|
$
|
0.16
|
|
Diluted
|
|
$
|
(0.11
|
)
|
|
$
|
0.16
|
|
Stock options excluded from the computation of diluted per
share amounts:
|
|
|
|
|
|
|
|
|
Weighted-average shares for which the exercise price
exceeds average market price of common stock
|
|
|
465
|
|
|
|
310
|
|
Average exercise price per share that exceeds average market
price of common stock
|
|
$
|
25.34
|
|
|
$
|
32.20
|
|
12. Commitments and Contingencies
Purchase Commitments
The Company has maintenance contracts with its equipment vendors for substantially all of its radiology and oncology equipment. The contracts are between one and seven years from inception and extend through the year 2022, but may be canceled by the Company under certain circumstances. The Company's total contract payments for the three months ended March 31, 2016 and 2015 were $10,284 and $9,887, respectively. At March 31, 2016, the Company had binding equipment purchase commitments totaling $28,909.
22
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
Guarantees and Indemnities
The Company has applied the disclosure provisions of ASC 460, “Guarantees,” to its agreements that contain guarantee or indemnification clauses. These disclosure provisions expand those required by ASC 440, “Commitments,” and ASC 450, “Contingencies,” by requiring a guarantor to disclose certain types of guarantees, even if the likelihood of requiring the guarantor's performance is remote.
In the normal course of business, the Company has made certain guarantees and indemnities, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain transactions. The Company indemnifies other parties, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed to hold the other party harmless against losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims arising from a breach of representations or covenants. In addition, the Company has entered into indemnification agreements with its executive officers and directors and the Company's bylaws contain similar indemnification obligations. Under these arrangements, the Company is obligated to indemnify, to the fullest extent permitted under applicable law, its current or former officers and directors for various amounts incurred with respect to actions, suits or proceedings in which they were made, or threatened to be made, a party as a result of acting as an officer or director.
It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. Historically, payments made related to these indemnifications have been immaterial. At March 31, 2016, the Company has determined that no liability is necessary related to these guarantees and indemnities.
Litigation
In November 2015, the Company was served with a lawsuit in the United States District Court for the Northern District of Ohio by Todd S. Elwert, DC, Inc. The Complaint alleges violations of the Junk Fax Prevention Act for allegedly sending an unsolicited advertisement to Plaintiff which promoted commercial availability and/or quality of the Company’s services. The Plaintiff further alleges that it is part of a class of similarly situated chiropractors who received the blast fax, and as such, requested class certification. The Company filed its response on December 17, 2015 and is currently in the discovery phase of the lawsuit.
Other Matters
The Company from time to time is involved in routine litigation and regulatory matters incidental to the conduct of its business. The Company believes that resolution of such matters will not have a material adverse effect on its consolidated financial statements.
13. Related-Party Transactions
Ownership Structure
On April 16, 2007, Oaktree and MTS purchased 4,900,301 shares of the Company’s common stock. Upon completion of the transaction, Oaktree and MTS owned in the aggregate approximately 50% of the outstanding shares of common stock of the Company. At March 31, 2015, Oaktree and MTS owned in the aggregate approximately 51% of the outstanding shares of common stock of the Company. The Company has not paid management fees to Oaktree and MTS for their financial advisory services to the Company.
On September 16, 2015, Fujian Thai Hot Investment Co., Ltd. (“Thai Hot”) agreed to purchase approximately 5,537,945 shares of Company common stock from funds managed by the Selling Stockholders for approximately $102.5 million or $18.50 per share. In connection with the Thai Hot Transaction, Thai Hot and the Selling Stockholders agreed to bear a specified portion of the following Company expenses related to the Thai Hot Transaction: (i) 100% of the fees and expenses incurred by the Company in connection with the amendment or waiver of its credit agreement, and (ii) all reasonable and documented fees and expenses incurred by the Company in connection with the Thai Hot Transaction in excess of $1 million. In addition, subject to the approval of the Board or an authorized special committee of the Board, Thai Hot agreed to fund a new management incentive arrangement which involves the issuance of $1.5 million in cash-based awards to the Company’s management. The expenses associated with the cash-based awards
23
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
will be recognized by the Company over the required service period of
the awards. The Company accounted for reimbursements received prior to the Thai Hot Transaction close from the Selling Stockholders of $15,343 as capital contributions and reimbursements received subsequent to the Thai Hot Transaction close from Thai Hot
of $13,500 as capital contributions. In addition, the Selling Stockholders
provided
$1.5 million related to the potential tax impact of the credit amendment costs incurred by the Company, measured after the close of the Thai Hot Transaction. It is possible
that all or a portion of the $1.5 million will be returned to the Selling Stockholders. Accordingly, the Company record the $1.5 million received as accrued liability on the Condensed Consolidated Balance Sheets.
The Thai Hot Transaction closed on March 29, 2016. As a result of the Thai Hot Transaction, Thai Hot owns an aggregate of approximately 51.5% of the outstanding shares of common stock of the Company. The Company has not agreed to pay any management fees to Thai Hot for any financial advisory services to the Company.
Management Agreements
The Company had direct ownership in two unconsolidated investees at March 31, 2016 and December 31, 2015. The Company obtained an additional 15.5% interest in one of its previously unconsolidated investees, AHNI, on August 1, 2015, thereby increasing its ownership position in AHNI to 65.5% and giving it a controlling interest.
Revenues from management agreements with unconsolidated equity investees were $353 and $2,378 during the three months ended March 31, 2016 and 2015, respectively. The Company provides services as part of its ongoing operations for and on behalf of the unconsolidated equity investees, which are included in the management agreement revenue, and reimburse the Company for the actual amount of the expenses incurred. The Company records the expenses as cost of revenues and the reimbursement as revenue in its Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income. For the three months ended March 31, 2016 and 2015, the amounts of the revenues and expenses were $252 and $1,947, respectively.
14. Investments in Unconsolidated Investees
The Company has direct ownership in two unconsolidated investees at March 31, 2016. The Company owns 15% and 50% of these investees, respectively, and provides management services under agreements with these investees, expiring at various dates through 2025. Both of these investees are accounted for under the equity method because the Company does not exercise control over the operations of these investees.
On August 1, 2015, the Company obtained an additional 15.5% interest in a previously unconsolidated investee, AHNI, thereby increasing its ownership position to 65.5% and giving it a controlling interest. Prior to August 1, 2015, the Company's interest in AHNI was deemed a noncontrolling interest and, as such, the Company accounted for the investment using the equity method.
Set forth below are certain operating results for the aggregate of the Company’s unconsolidated investees, including the operating results for AHNI for the three months ended March 31, 2015:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
Current assets
|
|
$
|
3,099
|
|
|
$
|
2,644
|
|
Noncurrent assets
|
|
|
163
|
|
|
|
273
|
|
Current liabilities
|
|
|
590
|
|
|
|
676
|
|
Noncurrent liabilities
|
|
|
35
|
|
|
|
35
|
|
24
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Operating Results:
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
2,301
|
|
|
$
|
4,164
|
|
Expenses
|
|
|
778
|
|
|
|
2,404
|
|
Net income
|
|
|
1,523
|
|
|
|
1,760
|
|
Earnings from unconsolidated investee
|
|
|
252
|
|
|
|
1,164
|
|
15. Stockholders’ Deficit
The following table summarizes consolidated stockholders’ deficit, including noncontrolling interest.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity (Deficit)
Attributable to
|
|
|
|
|
|
|
|
Common Stock
|
|
|
Treasury Stock
|
|
|
Additional
Paid-In
|
|
|
Accumulated
Comprehensive
|
|
|
Retained
Earnings
(Accumulated
|
|
|
Alliance
HealthCare
|
|
|
Non-controlling
|
|
|
Total
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income (Loss)
|
|
|
Deficit)
|
|
|
Services, Inc.
|
|
|
Interest
|
|
|
Equity (Deficit)
|
|
Balance at December 31,
2015
|
|
|
10,774,857
|
|
|
|
108
|
|
|
|
(157,973
|
)
|
|
|
(3,138
|
)
|
|
|
29,297
|
|
|
|
(511
|
)
|
|
|
(198,393
|
)
|
|
|
(172,637
|
)
|
|
|
95,017
|
|
|
|
(77,620
|
)
|
Exercise of stock options
|
|
|
100,000
|
|
|
|
1
|
|
|
|
—
|
|
|
|
—
|
|
|
|
485
|
|
|
|
—
|
|
|
|
—
|
|
|
|
486
|
|
|
|
—
|
|
|
|
486
|
|
Shareholder transaction
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
28,629
|
|
|
|
—
|
|
|
|
—
|
|
|
|
28,629
|
|
|
|
—
|
|
|
|
28,629
|
|
Share-based payment
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,402
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,402
|
|
|
|
—
|
|
|
|
1,402
|
|
Share-based payment
income tax benefit
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
345
|
|
|
|
—
|
|
|
|
—
|
|
|
|
345
|
|
|
|
—
|
|
|
|
345
|
|
Unrealized loss on
hedging transaction,
net of tax
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(38
|
)
|
|
|
—
|
|
|
|
(38
|
)
|
|
|
—
|
|
|
|
(38
|
)
|
Net investments in
subsidiaries
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(2,433
|
)
|
|
|
(2,433
|
)
|
Net income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(1,190
|
)
|
|
|
(1,190
|
)
|
|
|
4,592
|
|
|
|
3,402
|
|
Balance at March 31,
2016
|
|
|
10,874,857
|
|
|
|
109
|
|
|
|
(157,973
|
)
|
|
|
(3,138
|
)
|
|
|
60,158
|
|
|
|
(549
|
)
|
|
|
(199,583
|
)
|
|
|
(143,003
|
)
|
|
|
97,176
|
|
|
|
(45,827
|
)
|
16. Segment Information
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. In accordance with ASC 280, “Segment Reporting,” and based on the nature of the financial information that is received by the CODM, the Company operates in three operating segments (Radiology Division, Oncology Division, and Interventional HealthCare Services Division) that also qualify as reportable segments under the definition of ASC 280. Prior to 2016, the Company operated in two reportable business segments – Radiology and Oncology Divisions. Effective January 1, 2016, the Interventional HealthCare Services Division qualified as an additional reportable business segment. Accordingly, the information contained herein has been revised to reflect this change in presentation. Each of these reportable segments, on a stand-alone basis, provides and makes available their respective medical services in similar settings, and operates within a singular regulatory environment. Further, management assesses the segment operations and each segment’s degree of efficiency and performance based on this structure of financial reporting, and primarily makes operating decisions from these reportable segment results.
The radiology segment is comprised of diagnostic imaging services including MRI, PET/CT and other imaging services. The oncology segment is comprised of radiation oncology services. The interventional healthcare services operating segment is comprised of therapeutic minimally invasive pain management procedures medical management, laboratory testing, and other services. All intercompany revenues, expenses, payables and receivables are eliminated in consolidation and are not reviewed when evaluating segment performance. Each segment’s performance is evaluated based on Revenue, Segment Income and Net Income.
25
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The following table summarizes the Company’s revenue by segment:
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Revenue
|
|
|
|
|
|
|
|
|
Radiology
|
|
$
|
85,639
|
|
|
$
|
81,387
|
|
Oncology
|
|
|
26,062
|
|
|
|
24,186
|
|
Interventional
|
|
|
11,663
|
|
|
|
3,856
|
|
Corporate / Other
|
|
|
361
|
|
|
|
—
|
|
Total
|
|
$
|
123,725
|
|
|
$
|
109,429
|
|
The following are components of revenue:
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Revenue
|
|
|
|
|
|
|
|
|
MRI revenue
|
|
$
|
47,570
|
|
|
$
|
42,887
|
|
PET/CT revenue
|
|
|
31,666
|
|
|
|
31,550
|
|
Oncology
|
|
|
26,062
|
|
|
|
24,186
|
|
Interventional
|
|
|
11,663
|
|
|
|
3,856
|
|
Other radiology
|
|
|
6,403
|
|
|
|
6,950
|
|
Corporate / Other
|
|
|
361
|
|
|
|
—
|
|
Total
|
|
$
|
123,725
|
|
|
$
|
109,429
|
|
Segment income represents net income (loss) before income tax (benefit) expense; interest expense and other, net; amortization expense; depreciation expense; share-based payment; severance and related costs; noncontrolling interest in subsidiaries; restructuring charges; transaction costs; shareholder transaction costs; impairment charges; legal matters expense and other non-cash charges. Segment income is the most frequently used measure of each segment’s performance and is commonly used in setting performance goals. The following table summarizes the Company’s segment income:
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Segment income
|
|
|
|
|
|
|
|
|
Radiology
|
|
$
|
26,443
|
|
|
$
|
26,374
|
|
Oncology
|
|
|
12,157
|
|
|
|
11,763
|
|
Interventional
|
|
|
1,255
|
|
|
|
384
|
|
Corporate / Other
|
|
|
(9,483
|
)
|
|
|
(8,405
|
)
|
Total
|
|
$
|
30,372
|
|
|
$
|
30,116
|
|
26
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The reconciliation of n
et
(loss)
income to total segment income is shown below:
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Net (loss) income attributable to Alliance HealthCare
Services, Inc.
|
|
$
|
(1,190
|
)
|
|
$
|
1,751
|
|
Income tax (benefit) expense
|
|
|
(945
|
)
|
|
|
1,572
|
|
Interest expense and other, net
|
|
|
7,495
|
|
|
|
6,018
|
|
Amortization expense
|
|
|
2,443
|
|
|
|
2,035
|
|
Depreciation expense
|
|
|
13,048
|
|
|
|
11,633
|
|
Share-based payment (included in selling, general
and administrative expenses)
|
|
|
1,865
|
|
|
|
389
|
|
Severance and related costs
|
|
|
1,716
|
|
|
|
259
|
|
Noncontrolling interest in subsidiaries
|
|
|
4,592
|
|
|
|
4,347
|
|
Restructuring charges (Note 3)
|
|
|
231
|
|
|
|
255
|
|
Transaction costs
|
|
|
417
|
|
|
|
419
|
|
Shareholder transaction costs
|
|
|
1,009
|
|
|
|
—
|
|
Impairment charges
|
|
|
—
|
|
|
|
76
|
|
Legal matters expense (included in selling, general
and administrative expenses)
|
|
|
155
|
|
|
|
1,360
|
|
Other non-cash charges (included in other income
and expense, net)
|
|
|
(464
|
)
|
|
|
2
|
|
Total segment income
|
|
$
|
30,372
|
|
|
$
|
30,116
|
|
Net (loss) income for the radiology, oncology and interventional segments does not include charges for interest expense, net of interest income, income taxes or certain selling, general and administrative expenses. These costs are charged against the Corporate / Other segment. The following table summarizes the Company’s net income (loss) by segment:
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
Net (loss) income
|
|
|
|
|
|
|
|
|
Radiology
|
|
$
|
15,652
|
|
|
$
|
16,997
|
|
Oncology
|
|
|
4,186
|
|
|
|
5,024
|
|
Interventional
|
|
|
188
|
|
|
|
169
|
|
Corporate / Other
|
|
|
(21,216
|
)
|
|
|
(20,439
|
)
|
Total
|
|
$
|
(1,190
|
)
|
|
$
|
1,751
|
|
The following table summarizes the Company’s identifiable assets by segment:
|
|
As of March 31,
|
|
|
As of December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Identifiable assets
|
|
|
|
|
|
|
|
|
Radiology
|
|
$
|
294,914
|
|
|
$
|
280,497
|
|
Oncology
|
|
|
207,191
|
|
|
|
213,698
|
|
Interventional
|
|
|
87,143
|
|
|
|
83,480
|
|
Corporate / Other
|
|
|
28,397
|
|
|
|
25,985
|
|
Total
|
|
$
|
617,645
|
|
|
$
|
603,660
|
|
27
ALLIANCE HEALTHCARE SERVICES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS––(Continued)
March 31, 2016
(Unaudited)
(Dollars in thousands, except per share amounts)
The following table summarizes the Company’s goodwill by segment:
|
|
Radiology
|
|
|
Oncology
|
|
|
Interventional
|
|
|
Total
|
|
Balance at December 31, 2014
|
|
$
|
42,166
|
|
|
$
|
21,698
|
|
|
$
|
—
|
|
|
$
|
63,864
|
|
Goodwill acquired during the period
|
|
|
2,656
|
|
|
|
5,891
|
|
|
|
30,371
|
|
|
|
38,918
|
|
Impairment charges
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Adjustments to goodwill during the period
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Balance at December 31, 2015
|
|
$
|
44,822
|
|
|
$
|
27,589
|
|
|
$
|
30,371
|
|
|
$
|
102,782
|
|
Goodwill acquired during the period
|
|
|
—
|
|
|
|
—
|
|
|
|
929
|
|
|
|
929
|
|
Impairment charges
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Adjustments to goodwill during the period
|
|
|
—
|
|
|
|
615
|
|
|
|
(200
|
)
|
|
|
415
|
|
Balance at March 31, 2016
|
|
$
|
44,822
|
|
|
$
|
28,204
|
|
|
$
|
31,100
|
|
|
$
|
104,126
|
|
Gross goodwill
|
|
$
|
214,783
|
|
|
$
|
32,487
|
|
|
$
|
31,100
|
|
|
$
|
278,370
|
|
Accumulated impairment charges
|
|
|
(169,961
|
)
|
|
|
(4,283
|
)
|
|
|
—
|
|
|
|
(174,244
|
)
|
Balance at March 31, 2016
|
|
$
|
44,822
|
|
|
$
|
28,204
|
|
|
$
|
31,100
|
|
|
$
|
104,126
|
|
Capital expenditures in the radiology, oncology, interventional and corporate/other segments were $16,926, $484, $33 and $233 respectively for the three months ended March 31, 2016, and $6,830, $735, $0 and $0 respectively, for the three months ended March 31, 2015.
28